LDLR and type 1 diabetes mellitus: Lately, Laugier-Robiolle et al. investigated the association between proprotein convertase subtilisin/kexin type 9 (PCSK9), a post-transcriptional inhibitor of LDL-receptor, and plasma LDL-C in T1D patients classified by HbA1c; a better glycemic control was found able to abolish the positive relationship between PCSK9 and LDL-C in T1D patients45.